Category
Cancer
Sub Category
Gynecologic
Study Name
GOG-0283: A Phase II Trial of CDTD-Sponsored Dasatinib (NSC #732517 IND #120636) in Recurrent/Persistent Ovary, Fallopian Tube, Primary Peritoneal, and Endometrial Clear Cell Carcinoma Characterized for the Retention of Loss of BAF250A Expression
Principal Investigator
Gordan Srkalovic MD, PhD
Study Information
Contact for Questions
Sparrow Cancer Center 800-968-5570

Site view: at a glance